Kirill Vlaskov

Explored the role of T cell metabolic dysfunction in Chronic Lymphocytic Leukemia, focusing on mTOR signaling, glucose metabolism. Key contributions include: • Analyzed T cell activation and metabolic signaling using flow cytometry, protein synthesis assays, and extracellular flux analysis. • Identified two CLL T cell subgroups, revealing heterogeneous activation and metabolic responses. • Contributed to understanding mTOR signaling and glucose metabolism in T cells.

Analysed existing literature to unravel the significance of predictive biomarkers for toxicity in immune checkpoint inhibitors. Key contributions include: •Thoroughly examined mechanisms of action, distinguishing nuances in immune-related toxicities across inhibitors. •Explored the intricate relationship between efficacy and toxicity biomarkers, identifying their predictive potential. •Systematically reviewed additional biomarkers for toxicity prediction and evaluated variations across cancer types.

Researched the role of endothelial cells and mesenchymal stem cells in the progression of multiple myeloma within the bone marrow microenvironment. Key contributions include: •Optimized hiPSC differentiation protocols to generate induced EC, achieving up to 94% efficiency in endothelial marker expression. •Conducted co-culture experiments using luciferase-based assays assessing MM cell viability and interactions with EC and MSCs.

Conducted research on the role of SPAK in regulating circadian rhythms of blood pressure, heart rate, and physical activity in a SPAK knock-in mouse model. Key tasks included: •Used statistical methods to examine diurnal and nocturnal variations of telemetric data for blood pressure, heart rate, and physical activity. •Derived insights into SPAK’s regulatory role in circadian cardiovascular functions. •Developed understanding of blood pressure telemetry systems.